A landmark study co-authored by a Loyola Medicine oncologist has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia (CLL).
Like cartographers completing a map, investigators have identified multiple new subtypes of the most common childhood cancer—research that will likely improve the diagnosis and treatment of high-risk patients.
Mortality rates from the most common cancers continue to decline across the United States, with several notable exceptions, including liver cancer in men and especially in women, and also uterine cancer in women.
Writing in the January 3 issue of Cancer Cell, researchers at University of California San Diego School of Medicine report that detection of "copy editing" by a stem cell enzyme called ADAR1, which is active in more than 20 tumor types, may provide a kind of molecular radar for early detection of malignancies and represent a new therapeutic target for preventing cancer cell resistance to chemotherapy and radiation.
The FDA expanded the approval of dasatinib tablets to include its use with chemotherapy for children aged 1 year or older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Two drugs have been approved by the U.S. Food and Drug Administration for the treatment of rare blood diseases, the agency announced Friday. Elzonris (tagraxofusp-erzs) infusion was granted the first approval for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and children aged 2 years and older.
The researchers analyzed treatment outcomes and prognostic factors in adult patients with therapy-related myeloid neoplasms (t-MNs) to select patients who would be benefited by active anticancer treatment
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is the leading cause of death worldwide. This Mendelian randomization study uses genetic variants as instruments to investigate whether there is a causal effect of genetically determined platelet count on CAD and ischemic stroke risk.
Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease with various clinical manifestations. MicroRNAs (miRNAs) and immunometabolism are recognized as key elements in SLE pathogenesis; However, the relationship between miRNAs and peripheral blood mononuclear cells (PBMCs) and metabolism in SLE remains unclear.
Patients treated with chemotherapy for a solid tumor are at much higher risk than was previously thought of developing a highly lethal blood cancer as a result of that treatment.
Scientists at the University of Glasgow have discovered a potential combination therapy for the treatment of chronic lymphocytic leukemia (CLL), the most common form of leukemia in the Western world, diagnosed in more than 3,500 people in the UK each year.